Vivek Gupta

Assistant Professor
PhD, Pharmaceutical Sciences, Texas Tech University Health Sciences Center (2010)BS, Pharmaceutical Sciences, Jamia Hamdard (University) (2003)Post-Doctoral Training: Department of Chemical Engineering, University of California Santa Barbara (2011-2013)

LinkedIn Profile

Research Website

Dr Vivek Gupta is an associate professor of industrial pharmacy at College of Pharmacy & Health Sciences. Before joining St. John’s University in September 2016, Dr Gupta was an assistant professor of pharmaceutics at Keck Graduate Institute School of Pharmacy in Claremont, CA (2013-2016).

Dr Gupta's is an experienced pharmaceutical researcher with interests in developing novel therapies for respiratory disorders. His expertise lies in the fields of novel drug discovery and repurposing, and non-invasive delivery of small and macromolecules via oral and inhalation routes. He also has significant research interest in the fields of pharmaceutical scalability, and nano-repurposing. Diseases of interest include lung cancer, pulmonary fibrosis, pulmonary hypertension, and mesothelioma.

Dr. Gupta’s lab at St. John’s is very well-equipped with the most updated formulation development and analytical equipment; and is consistently funded by federal and pharmaceutical industry research grants. Dr. Gupta’s research group has published >75 high-impact publications in peer reviewed journals like Journal of Controlled Release, Materials Science & Engineering C, Drug Discovery Today, Pharmaceutical Research to name a few. Dr. Gupta also serves on editorial boards of many peer-reviewed journals including PLOS One, Pharmaceutical Research, International Journal of Molecular Sciences, to name a few; and is also involved in national pharmaceutical organizations including AAPS and CRS.

Multiple technologies and therapies developed by Dr. Gupta’s group have been patented and are at various stages of preclinical/clinical development. Dr. Gupta is also the current chapter adviser for St. John’s-AAPS Student Chapter; and is organizer of Annual Charles Jarowski Symposium in Pharmaceutical Sciences.

Teaching Interests

Pharmaceutics, Pharmacokinetics, Pharmaceutical Compounding, Targeted Drug Delivery, Pharmaceutical Analysis

Research Interests

Inhalation, Pulmonary delivery, Rare Diseases, Pharmaceutical scalability, Respiratory diseases, Drug Repurposing and Repositioning, Mesothelioma, Pulmonary hypertension, Pulmonary fibrosis, Lung cancer

Courses Taught

Undergraduate

BMS 1000 SEMINARS IN BIOMEDICAL SCIENCES

PHS 4601 EXTEMPORANEOUS COMPOUNDING

PHS 4602 BIOPHA & BASIC PHARMACOKINETICS

PHS 3601 PHARMACEUTICS – I

PHS 3151 CALCULATIONS IN PHARMACY PRACTICE

Graduate

IPP 250 TARGETED DRUG DELIVERY SYSTEMS

IPP 233 INDUSTRIAL PHARM JOURNAL CLUB

PHS 256 PHARMACEUTICAL ANALYSIS

Current Lab Personnel:

Nishant S Kulkarni – PhD Candidate

Xuechun (Lucy) Wang – PhD Candidate

Gautam Chauhan – PhD Candidate

Sruthi Sarvepalli – PhD Candidate

Mimansa Goyal – PhD Candidate

Select Publications

Journal Articles

Selected Publications (2020 onwards)

For full list, visit PUBMED or GOOGLE SCHOLAR (>3,000 Citations, H-index – 28)

  1. Parvathaneni V, Elbatanony R, Goyal M, Chavan T, Vega N, Kolluru S, Muth A, Gupta V*, Kunda NK* (2021). Repurposing Bedaquiline for Effective Non-small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-based Molecular Inclusion Complexes. International Journal of Molecular Sciences (Accepted April 27, 2021).
  2. Kulkarni NS, Vaidya B, Gupta V* (2021). Nano-synergistic Combination of Erlotinib and Quinacrine for Non-Small Cell Lung Cancer (NSCLC) Therapeutics – Evaluation in Biologically Relevant In-vitro Models. Materials Science and Engineering C 121:Feb 2021:111891.
  3. Parvathaneni V, Elbatanony R, Shukla SK, Kulkarni NS, Kanabar DD, Chauhan G, Ayehunie S, Chen ZS, Muth A, Gupta V*(2020). Bypassing P-glycoprotein Mediated Efflux of Afatinib by Cyclodextrin Complexation – Evaluation of Intestinal Absorption and Anti-Cancer Activity. Journal of Molecular Liquids (Available online November 25, 2020).
  4. Kulkarni NS, Vaidya B, Parvathaneni V, Bhanja D, Gupta V*(2020). Repurposing Quinacrine for Treatment of Malignant Mesothelioma – In-vitro Therapeutic and Mechanistic Evaluation. International Journal of Molecular Sciences 21(17):E6306.
  5. Parvathaneni V, Gupta V* (2020). Utilizing Drug Repurposing against COVID-19 – Efficacy, Limitations and Challenges. Life Sciences 259:118275.
  6. Chauhan G, Shaik AA, Kulkarni NS, Gupta V* (2020). The Preparation of Lipid-Based Drug Delivery Systems using Melt Extrusion. Drug Discovery Today S1359-6446(20)30330-5.
  7. Wang X, Parvathaneni V, Shukla SK, Kulkarni NS, Muth A, Kunda NK, Gupta V* (2020). Inhalable Resveratrol-Cyclodextrin Complex Loaded Biodegradable Nanoparticles for Enhanced Efficacy against Non-Small Cell Lung Cancer. International Journal of Biological Macromolecules 164:638-650.
  8. Wang X, Parvathaneni V, Shukla SK, Kanabar DD, Muth A, Gupta V* (2020). Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrol – Applications in Non-Small Cell Lung Cancer Treatment. AAPS PharmSciTech 21(5):183.
  9. Parvathaneni V, Goyal M, Kulkarni NS, Shukla SK, Gupta V* (2020). Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research 37(7):123.
  10. Parvathaneni V, Kulkarni NS, Chauhan G, Shukla SK, Elbatanony R, Patel BI, Kunda NK, Muth A, Gupta V* (2020). Development of Pharmaceutically Scalable Inhaled Anti-cancer Nanotherapy – Repurposing Amodiaquine for Non-Small Cell Lung Cancer (NSCLC). Materials Science and Engineering C 115:111139.
  11. Shukla SK, Chan A, Parvathaneni V, Gupta V*(2020). Metformin-loaded Chitosomes for Treatment of Malignant Pleural Mesothelioma – A Rare Thoracic Cancer. International Journal of Biological Macromolecules 160:128-141.
  12. Parvathaneni V, Kulkarni NS, Shukla SK, Farrales PT, Kunda NK, Muth A, Gupta V* (2020). Systemic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. Pharmaceutics 12(3):206.
  13. Shukla SK, Kulkarni NS, Farrales P, Kanabar DD, Parvathaneni V, Kunda NK, Muth A, Gupta V*(2020). Sorafenib Loaded Inhalable Polymeric Nanoparticles against Non-Small Cell Lung Cancer. Pharmaceutical Research 37(3):67.
  14. Shukla SK, Kadry H, Bhatt J, Elbatanony R, Ahsan F, Gupta V* (2020). Statistical Optimization and Validation of a Novel UPLC Method for Estimation of Nintedanib in Rat and Human Plasma. Bioanalysis 12(3):159-174.
  15. Vaidya B, Kulkarni NS, Shukla SK, Parvathaneni V, Chauhan G, Damon JK, Sarode A, Garcia JV, Kunda NK, Mitragotri S, Gupta V* (2020). Development of Inhalable Quinacrine Loaded Bovine Serum Albumin Modified Cationic Nanoparticles: Repurposing Quinacrine for Lung Cancer Therapeutics. International Journal of Pharmaceutics 577(2020):118995.

Current Funding

  1. National Institutes of Health (NIH)-NHLBI
  2. American Heart Association (AHA)
  3. ProdiGY Biotech
  4. Radius Health
  5. PulmoSIM Therapeutics